Heart rate reduction and cardiovascular outcomes: is there a therapeutic relation?

被引：0

作者：

Borer, J. S. ^{[1
]}

机构：

[1] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA

来源：

NEW HORIZONS IN CARDIOVASCULAR DISEASES | 2010年

关键词：

CURRENT INHIBITOR IVABRADINE; CORONARY-ARTERY-DISEASE; CHRONIC STABLE ANGINA; I-F INHIBITOR; DOUBLE-BLIND; BETA-BLOCKER; FAILURE; TRIAL; RISK;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recent data suggest benefit from heart rate (HR) reduction in in several heart conditions. The pure HR slowing I-f channel blocker, ivabradine (acting solely to slow spontaneous d(i)astolic depolarization in the sino-atrial node) is approved (Europe) for preventing angina pectoris (as effectively as beta and calcium channel blockers) in patients (pts) with coronary artery disease (CAD). Also, in pts with chronic stable CAD and HR >= 70bpm, BEAUTIFUL data suggest ivabradine reduces fatal and non-fatal myocardial infarction and indications for revascularization (particularly in pts with angina); small clinical trials also suggest improved cardiac function and symptoms in patients with heart failure and systolic dysfunction. The SHIFT study now has defined the drug's efficacy for reducing cardiovascular deaths or hospitalizations by 18% on top of standard background therapy when pre-therapy HR is >= 70bpm.

引用

收藏

页码：161 / 164

页数：4

相关论文

共 23 条

[1] Can we improve cardiovascular risk prediction beyond risk equations in the physician's office? [J].

Aboyans, Victor ;

Criqui, Michael H. .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 2006, 59 (06) :547-558

[2] SUBSETS OF AMBULATORY MYOCARDIAL-ISCHEMIA BASED ON HEART-RATE ACTIVITY - CIRCADIAN DISTRIBUTION AND RESPONSE TO ANTIISCHEMIC MEDICATION [J].

ANDREWS, TC ;

FENTON, T ;

TOYOSAKI, N ;

GLASSER, SP ;

YOUNG, PM ;

MACCALLUM, G ;

GIBSON, RS ;

SHOOK, TL ;

STONE, PH .

CIRCULATION, 1993, 88 (01) :92-100

[3] The Prevalence of Weekly Angina Among Patients With Chronic Stable Angina in Primary Care Practices The Coronary Artery Disease in General Practice (CADENCE) Study [J].

Beltrame, John F. ;

Weekes, Andrew J. ;

Morgan, Claire ;

Tavella, Rosanna ;

Spertus, John A. .

ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (16) :1491-1499

[4]

Boehm M, 2010, LANCET, DOI [10.1016/S0140-6736(10)61259-7, DOI 10.1016/S0140-6736(10)61259-7]

[5] Heart rate slowing by If inhibition:: therapeutic utility from clinical trials [J].

Borer, JS .

EUROPEAN HEART JOURNAL SUPPLEMENTS, 2005, 7 (0H) :H22-H28

[6] Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina -: A randomized, double-blind, multicentered, placebo-controlled trial [J].

Borer, JS ;

Fox, K ;

Jaillon, P ;

Lerebours, G .

CIRCULATION, 2003, 107 (06) :817-823

[7]

BORER JS, 2004, NATURE CLIN PRACTICE, V1, P1

[8] Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure [J].

De Ferrari, Gaetano M. ;

Mazzuero, Antonio ;

Agnesina, Laura ;

Bertoletti, Alessandra ;

Lettino, Maddalena ;

Campana, Carlo ;

Schwartz, Peter J. ;

Tavazzi, Luigi .

EUROPEAN JOURNAL OF HEART FAILURE, 2008, 10 (06) :550-555

[9] Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers [J].

Flannery, Genevieve ;

Gehrig-Mills, Rosie ;

Billah, Baki ;

Krum, Henry .

AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (06) :865-869

[10] Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial [J].

Fox, Kim ;

Ford, Ian ;

Steg, P. Gabriel ;

Tendera, Michal ;

Ferrari, Roberto .

LANCET, 2008, 372 (9641) :807-816